FSSAI issues notices to Nestle India over Lactogen, Nan Excella claims

The Food Safety and Standards Authority of India (FSSAI) on Monday issued notices to Nestlé India Limited over claims made on two of its infant nutrition products.

 

The food regulator flagged, in social media posts, a claim on Lactogen Pro 1 Powder’s packaging and advertising material: “contains Whey Protein, which is a part of milk protein that is easy to digest.” FSSAI asked the company to furnish scientific substantiation for the claim. It also directed Nestlé to submit the requisite documents and supporting evidence within the stipulated period.

 

Nestle India's spokesperson said: FSSAI’s recent post reiterates the points raised in its earlier post of 18 September regarding product labels. We have already submitted our detailed response to FSSAI on these matters.

More on the subject

• 1Consumption stocks: Bet now or wait for festive sales to show recovery?
• 2Inflation puts FMCG firms' margins at risk; analysts back Marico, Nestle
• 3Two-wheeler stocks: Can the onset of festive demand offset weak monsoon?
• 4Consumer durables buck FPI exodus in FY27; festive demand to test momentum
• 5Stock Market LIVE: Sensex trades flat; SBI's CS Setty says 'minimal MDR useful to the system'
• 6Sydney data centre plan scrapped by developer after community backlash
• 7NMS Created: Infosys Q2 results preview: Analysts see PAT rising 10%;
• 8Shree Renuka, Balrampur & others fall up to 6%; why are sugar stocks down?
• 9Sydney data centre plan scrapped by developer after community backlash
• 10India to host IPL 2027 player auction; first time since 2023: Report
• 11Permalink QA test article
• 12Anthropic says it blocked AI use linked to biological weapons research
• 13Ghosts of the past haunt defence FDI
• 14Anthropic says it blocked AI use linked to biological weapons researchaa
• 15Direct plans gain in long-term SIPs, but regular plans continue to dominate
• 16Swiggy Q2 net loss narrows 15.6% to ₹922 crore, revenue rises 36%
• 17Leading NBFCs flag early signs of repayment stress in gold loan segment
• 18FSSAI issues notices to Nestle India over Lactogen, Nan Excella claims
• 19Tata Steel commissions ₹9,067 crore facilities at Kalinganagar plants

More

 

In the second notice, FSSAI examined the claim on Nan Excella Pro Stage 1: “5 HMOs helps support the normal immune system.” The regulator considered it to imply that the product is suitable for supporting the immune system, suggesting its use in relation to a particular physiological condition.

 

FSSAI said the claim was non-compliant with provisions that prohibit claims relating to the prevention, alleviation, treatment or cure of any disease, disorder or physiological condition, unless specifically permitted under applicable regulations.